- Conditions
- Papulopustular Rosacea
- Interventions
- CD5024, Azelaic acid 15% Gel
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 10,865
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autism Spectrum Disorder, Developmental Delay
- Interventions
- BioROSA MAP test
- Diagnostic Test
- Lead sponsor
- BioROSA Technologies Inc
- Industry
- Eligibility
- 18 Months to 60 Months
- Enrollment
- 200 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Metabolic Syndrome, Hypertension
- Interventions
- Placebo, Enalapril 5mg, Enalapril 10mg, Sitagliptin
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
- Interventions
- palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 35
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Interventions
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Radiation · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 212
- States / cities
- Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
- Conditions
- Endometrial Cancer
- Interventions
- conjugated estrogens
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 2,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more
- Conditions
- Healthy Adults, Stress
- Interventions
- Slow breathing
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- West Nile Fever Encephalitis
- Interventions
- WN/DEN4-3'delta30, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Nashville, Tennessee
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
- Conditions
- Prostate Cancer
- Interventions
- tarenflurbil, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
- Conditions
- Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
- Interventions
- Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo, Niraparib-Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 65
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Epilepsy
- Interventions
- Placebo, Rufinamide
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 77
- States / cities
- Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
- Conditions
- Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
- Interventions
- Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
- Drug
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 11
- States / cities
- Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- afatinib, placebo
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 272
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 Immunogen
- Biological
- Lead sponsor
- The Immune Response Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
- Conditions
- Sepsis
- Interventions
- Conservative Fluid Management Strategy
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ovarian Cancer
- Interventions
- avelumab, PLD
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 87
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more
- Conditions
- Pseudobulbar Affect (PBA)
- Interventions
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
- Conditions
- Atrial Fibrillation
- Interventions
- Patients with Atrial Fibrillation
- Other
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 13,769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 217
- States / cities
- Cullman, Alabama • Dothan, Alabama • Fairhope, Alabama + 214 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Placebo, GC33
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Bethesda, Maryland • Detroit, Michigan + 4 more
- Conditions
- Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma
- Interventions
- medical chart review, questionnaire administration, management of therapy complications
- Other · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 15
- States / cities
- Palo Alto, California • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Meniere Disease
- Interventions
- OTO-104, Placebo
- Drug
- Lead sponsor
- Otonomy, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 17
- States / cities
- Fresno, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
- Conditions
- Knee Arthroscopy, General Anesthesia, Subarachnoid Block
- Interventions
- General anesthesia, Subarachnoid block
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee